Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma

Fig. 2

Elevated ASAP2 expression levels predict poor prognosis in hepatocellular carcinoma (HCC). A Prognostic value of ASAP2 in predicting overall survival (OS), recurrence-free survival (RFS), and progression-free survival (PFS) in the entire The Cancer Genome Atlas (TCGA) Liver hepatocellular carcinoma (LIHC) cohort. B Prognostic value of ASAP2 in predicting OS, RFS, and PFS in patients with hepatitis in TCGA LIHC cohort. C Typical images of ASAP2 expression in HCC tissues collected from Fudan University Shanghai Cancer Center (FUSCC, left), and death and recurrence rates of HCC patients with distinct ASAP2 states (right). D Kaplan–Meier curve analysis of ASAP2 expression for predicting RFS (left) and OS (right) in patients from FUSCC. E, F Univariate Cox regression analysis of ASAP2 and other clinicopathological parameters for predicting RFS (left) and OS (right) in patients from FUSCC

Back to article page